TriGemX Bio uses the science of gut-brain biology to create medicines that transform human health.
TriGemX Bio has raised $94.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in October 2026.
TriGemX Bio's investors include TCG Crossover, Lux Capital, Viking Global Investors, StepStone Group, The Column Group.
TriGemX Bio is headquartered in New York, United States.
TriGemX Bio uses the science of gut-brain biology to create medicines that transform human health.
TriGemX Bio is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"TriGemX Bio — Funding & Investors." VCBacked, October 1, 2026, https://www.vcbacked.co/company/trigemx-bio. Accessed November 12, 2026.
VCBacked. (2026). TriGemX Bio — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/trigemx-bio
{{cite web |title=TriGemX Bio — Funding & Investors |url=https://www.vcbacked.co/company/trigemx-bio |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at TriGemX Bio? Request a listing update